Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
University Hospital, Ghent
Age
18–80
Sex
MALE
Healthy volunteers
Not accepted
You may be eligible if
Histologically proven diagnosis of prostate cancer (PCa)
Biochemical relapse of PCa following radical local prostate treatment
N1 and M1a/b disease on imaging, with a combined maximum of 3 synchronous lesions.
World Health Organization (WHO) performance state 0-1
Exclusion of local relapse
Age \>=18 years old
Signed informed consent
You may not be if
Serum testosterone level \<50ng/ml
Symptomatic metastases
PSA rise while on active treatment with luteinizing hormone-releasing hormone (LHRH)-agonist, LHRH-antagonist, anti-androgen, maximal androgen blockade, oestrogen
Previous treatment with cytotoxic agent for PCa
Treatment during the past month with products known to influence Prostate Specific Antigen (PSA) levels (e.g. fluconazole, finasteride, corticosteroids,…)
Disorder precluding understanding of trial information or informed consent
